Literature DB >> 3503594

Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine.

M Chung1, D P Reitberg, M Gaffney, W Singleton.   

Abstract

The pharmacokinetics of nifedipine following intravenous administration can be represented by an open two-compartment model with a terminal elimination half-life of about two hours. Nifedipine is extensively biotransformed to inactive metabolites, and the total body clearance (450 to 700 ml/minute) is primarily due to hepatic metabolism. Nifedipine undergoes significant tissue distribution in that the steady-state volume of distribution (0.62 to 0.77 liter/kg) is more than twice the volume of distribution of the central compartment (0.25 to 0.29 liter/kg). Although nifedipine is almost completely absorbed from the gastrointestinal tract, oral bioavailability ranges from 45 to 68 percent because of first-pass metabolism. Nifedipine given three times daily shows no accumulation in plasma and no changes in pharmacokinetic behavior during a one-week study period. Pharmacokinetic studies on the gastrointestinal therapeutic system (GITS) show that the bioavailability of the GITS dosage form (relative to the capsule) is about 65 percent after a single dose, but increases to about 86 percent at steady-state because of residual absorption more than 24 hours after dosing. Linear pharmacokinetics are seen following administration of single oral doses of nifedipine GITS as indicated by dose-proportional increases in the area under the plasma drug concentration-time curve over the range of 30 to 180 mg. Administration of the GITS dosage form in the presence of food slightly increases the rate of drug absorption, but does not influence the extent of drug bioavailability. Dose-dumping has not been observed, even with dosing after a meal containing a high level of fat. The GITS tablets provide zero-order delivery of nifedipine, and drug absorption persists beyond the dosing interval of 24 hours. Thus, the GITS dosage form will permit once-a-day dosing and maintain the desired, constant plasma drug concentration with minimal fluctuation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3503594     DOI: 10.1016/0002-9343(87)90630-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  30 in total

Review 1.  Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Authors:  Yie W Chien; Senshang Lin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Drug delivery systems for treatment of systemic hypertension.

Authors:  L Michael Prisant; William J Elliott
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.

Authors:  M Chung; V Vashi; J Puente; M Sweeney; P Meredith
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 5.  How important is 24-hour control of blood pressure?

Authors:  T Morgan; A Anderson
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

Review 6.  Review of the diagnosis and management of gastrointestinal bezoars.

Authors:  Masaya Iwamuro; Hiroyuki Okada; Kazuhiro Matsueda; Tomoki Inaba; Chiaki Kusumoto; Atsushi Imagawa; Kazuhide Yamamoto
Journal:  World J Gastrointest Endosc       Date:  2015-04-16

Review 7.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 8.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

Review 9.  Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.

Authors:  P D Pearigen; N L Benowitz
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

10.  Morning versus evening administration of nifedipine gastrointestinal therapeutic system in the management of essential hypertension.

Authors:  P Greminger; P M Suter; D Holm; R Kobelt; W Vetter
Journal:  Clin Investig       Date:  1994-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.